Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Biogen Ma Inc patents (2015 archive)

Recent patent applications related to Biogen Ma Inc. Biogen Ma Inc is listed as an Agent/Assignee. Note: Biogen Ma Inc may have other listings under different names/spellings. We're not affiliated with Biogen Ma Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Biogen Ma Inc-related inventors

12/24/15 / #20150366803

Nrf2 screening assays and related methods and compositions

Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (ms). The compounds described upregulate the cellular cytoprotective pathway regulated by nrf2. ... Biogen Ma Inc

12/17/15 / #20150361417

Assay for detection of jc virus dna

In one aspect, the disclosure provides methods for isolating nucleic acid from a cerebrospinal fluid (csf) sample. In one aspect, the disclosure provides methods for determining the amount of jc virus dna in a sample.. ... Biogen Ma Inc

12/17/15 / #20150361158

Optimized factor viii gene

The present invention provides codon optimized factor viii sequences, vectors and host cells comprising codon optimized factor viii sequences, polypeptides encoded by codon optimized factor viii sequences, and methods of producing such polypeptides.. . ... Biogen Ma Inc

12/17/15 / #20150361029

S1p modulating agents

Compounds of formula (i) can modulate the activity of one or more s 1p receptors. Sphingosine 1-phosphate (s ip) is a lysophospholipid mediator that evokes a variety of cellular responses by stimulation of five members of the endothelial cell differentiation gene (edg) receptor family, namely s1p1, s1p2, s1p3, s1p4, and s1p5 (formerly edg1, edg5, edg3, edg6 and edg8). ... Biogen Ma Inc

12/10/15 / #20150353883

Medium supplements for improved process performance

The present invention pertains to a cell culture medium comprising dextran sulfate or a mixture of dextran sulfate and ferric citrate, and methods of using thereof. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with dextran sulfate or a mixture of dextran sulfate and ferric citrate.. ... Biogen Ma Inc

11/19/15 / #20150329638

Use of dr6 antagonists to improve motor neuron disease

The present invention relates to death receptor-6 (dr6) antagonists and methods of their use in improving motor neuron disease. Novel affinity enhanced anti-dr6 antibodies are also provided. ... Biogen Ma Inc

11/05/15 / #20150315273

Sp35 antibodies and uses thereof

Endogenous sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous sp35 function, such anti-sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. ... Biogen Ma Inc

10/22/15 / #20150299325

Anti-blood dendritic cell antigen 2 antibodies and uses thereof

Antibodies and antibody fragments that bind to bdca2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.. ... Biogen Ma Inc

10/22/15 / #20150299323

Antibodies to vla-1

Antibodies that specifically bind to vla-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by vla-1 antibodies and their ligands, and vla-1 antagonists and agonists identified by using the structure coordinates of these structures.. ... Biogen Ma Inc

10/01/15 / #20150274808

Methods of preventing and removing trisulfide bonds

The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. ... Biogen Ma Inc

09/24/15 / #20150266943

Factor viii complex with xten and von willebrand factor protein, and uses thereof

The present invention includes a chimeric protein comprising a vwf protein with d′ domain and d3 domain of vwf, one or more xten sequence, and a fviii protein, wherein the vwf fragment, the xten sequence, or the fviii protein are linked to or associated with each other. The chimeric protein can further comprise one or more ig constant region or a portion thereof (e.g., an fc region). ... Biogen Ma Inc

07/30/15 / #20150209318

Pharmaceutical compositions containing dimethyl fumarate

Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.. . ... Biogen Ma Inc

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Biogen Ma Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Biogen Ma Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by